1-7 of 7
Susan Wroblewski
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without Daratumumab

Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Paula Rodriguez Otero, Meletios A. Dimopoulos, Tomoaki Fujisaki, Jae Hoon Lee, Susan Wroblewski, Fredrik Borgsten, Robin Carson, Rui Liu, Man Zhao, Tingting Wu, Xi Chen, Canchan Cui, Jian Hou, Jianxiang Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 2006.
https://doi.org/10.1182/blood-2023-180809
Published: 2023
Journal Articles

Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone

Jian Hou, Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, CS Chim, Paula Rodriguez-Otero, Meletios A. Dimopoulos, Tomoaki Fujisaki, Jae Hoon Lee, Susan Wroblewski, Robin Carson, Ming Qi, Jianping Wang, Yang Song, Bin Jia, Xue Yang, Wenyu Liu, Yunan Li, Renyi Zhang, Jianxiang Wang
Journal: Blood
Blood (2021) 138 (Supplement 1): 1661.
https://doi.org/10.1182/blood-2021-146974
Published: 2021
Journal Articles

Progression-Free Survival Outcomes By Response Status for Bortezomib, Melphalan, and Prednisone with or without Daratumumab in Newly Diagnosed Multiple Myeloma: Pooled Subgroup Analysis of Octans and Alcyone

Jianxiang Wang, Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, CS Chim, Paula Rodriguez-Otero, Anna Marina Liberati, Hiroyuki Takamatsu, Jae Hoon Lee, Meletios A. Dimopoulos, Susan Wroblewski, Robin Carson, Ming Qi, Jianping Wang, Yang Song, Bin Jia, Xue Yang, Wenyu Liu, Yunan Li, Renyi Zhang, Jian Hou
Journal: Blood
Blood (2021) 138 (Supplement 1): 1648.
https://doi.org/10.1182/blood-2021-148937
Published: 2021
Journal Articles

Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone

Paula Rodriguez-Otero, Mario Boccadoro, Roman Hajek, MD, Tomoaki Fujisaki, MD, Jae Hoon Lee, MD PhD, Joaquin Martinez-Lopez, MD, Paulo Lucio, MD PhD, Zsolt Nagy, MD PhD, Ganna Usenko, MD, Anna Marina Liberati, MD, Mihaela Lazaroiu, MD, Dariusz Woszczyk, MDPhD, Hiroyuki Takamatsu, MDPhD, Joanna Romejko-Jarosinska, Stefan Tobias Knop, Astrid Pavlovsky, MD, Cecily Forsyth, FRACP, FRCPA, MBBS, Takayuki Ishikawa, MD PhD, Katharine S. Gries, PhD PharmD, Huiling Pei, PhD, Anupa Kudva, MD, Jon Ukropec, PhD, Susan Wroblewski, PhD, Robin Carson, MD BA, Meletios A Dimopoulos
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-136145
Published: 2020
Journal Articles

Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma Who Have Been Previously Treated with Intravenous Daratumumab to Evaluate Retreatment (LYNX)

Nizar Bahlis, MD, Jeffrey A. Zonder, Susan Wroblewski, PhD, Ming Qi, MD PhD, Thomas Renaud, Carolyn Jackson, Thierry Facon, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1831.
https://doi.org/10.1182/blood-2019-123486
Published: 2019
Journal Articles

Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone

Maria-Victoria Mateos, Michele Cavo, Joan Bladé, MD PhD, Meletios A. Dimopoulos, MD, Kenshi Suzuki, MD PhD, Andrzej Jakubowiak, MD PhD, Stefan Knop, Chantal Doyen, MD, Paulo Lucio, MD PhD, Zsolt Nagy, MD PhD, Ludek Pour, MD, Mark Cook, MBChB,PhD, Sebastian Grosicki, MD PhD, Andre H Crepaldi, MD, Anna Marina Liberati, Philip Campbell, MBBS, FRACP, FRCPA, Tatiana Shelekhova, Sung-Soo Yoon, MD PhD, Genadi Iosava, MD, Tomoaki Fujisaki, MD PhD, Mamta Garg, MD FRCP, FRCPath, Maria Krevvata, PhD, Jianping Wang, Anupa Kudva, MD, Jon Ukropec, PhD, Susan Wroblewski, PhD, Rachel Kobos, MD, Jesús San-Miguel
Journal: Blood
Blood (2019) 134 (Supplement_1): 859.
https://doi.org/10.1182/blood-2019-123401
Published: 2019
Journal Articles

One-Year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Alcyone

Meletios A Dimopoulos, MD, Maria-Victoria Mateos, MD PhD, Michele Cavo, MD, Kenshi Suzuki, MD PhD, Andrzej Jakubowiak, MD PhD, Stefan Knop, Chantal Doyen, MD, Paulo Lucio, Zsolt Nagy, MD PhD, Polina Kaplan, Ludek Pour, MD, Mark Cook, MBChB,PhD, Sebastian Grosicki, MD PhD, Andre H Crepaldi, MD, Anna Marina Liberati, MD, Philip Campbell, MBBS, FRACP, FRCPA, Tatiana Shelekhova, Sung-Soo Yoon, MD PhD, Genadi Iosava, MD, Tomoaki Fujisaki, MD PhD, Mamta Garg, Christopher Chiu, PhD, Jianping Wang, Anupa Kudva, Rachel Kobos, MD, Susan Wroblewski, PhD, Ming Qi, MD PhD, Jesus F San-Miguel, MD PhD, Joan Bladé, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 156.
https://doi.org/10.1182/blood-2018-156
Published: 2018